Myeloma patients may soon ditch daily pills if cancer stays hidden

NCT ID NCT05192122

Recruiting now Disease control Sponsor: University of Illinois at Chicago Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study is testing whether multiple myeloma patients who have no detectable cancer cells (called MRD-negative) after a stem cell transplant can safely stop their daily maintenance drugs. Fifty participants will be followed closely with bone marrow tests to see if their cancer stays away. The goal is to reduce the burden of long-term medication without increasing the risk of relapse.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: discontinuation of maintenance therapy (lenalidomide or similar)
What this could lead to: If successful, this could show that some patients with no detectable cancer can safely stop daily maintenance drugs without their disease returning quickly.
What could go wrong: This is a very early, small pilot study (50 people). It is not yet known if stopping therapy is safe long-term, and some patients may relapse sooner.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

University of Illinois Cancer Center
RECRUITING

Chicago, Illinois, 60612, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.